$6.03 +0.24 (%) Alimera Sciences Inc - NASDAQ

Nov. 26, 2014 | 04:00 PM

Partner Headlines

  1. Alimera Sciences Inc Extends Gains On FDA News

    Benzinga | Sep. 29, 2014 | 10:59AM EST
  2. Morning Market Movers

    Benzinga | Sep. 29, 2014 | 09:36AM EST
  3. Benzinga's Top #PreMarket Gainers

    Benzinga | Sep. 29, 2014 | 08:10AM EST
  4. Morning Market Movers

    Benzinga | Jun. 30, 2014 | 09:40AM EST
  5. Benzinga's Top #PreMarket Gainers

    Benzinga | Jun. 30, 2014 | 08:05AM EST
  6. Alimera Sciences Announces Sept 26th PDUFA Date for ILUVIEN

    Benzinga | Apr. 14, 2014 | 07:25AM EST
  7. Mid-Morning Market Update: Markets Open Higher; Francesca's Issues Downbeat Q1 Forecast

    Benzinga | Mar. 26, 2014 | 10:24AM EST
  8. Mid-Day Losers Mar. 7, 2014: PXLW, ALOG, ALSK, NMRX, NLNK, EMAN

    Benzinga | Mar. 7, 2014 | 11:34AM EST
  9. Morning Movers for Mar. 7, 2014: SKUL, DLIA, BIG, GTAT, CCRN, FL Moving Higher; NLNK, FEYE, SWY, FCEL Lower

    Benzinga | Mar. 7, 2014 | 09:04AM EST
  10. Is The Market On Drugs?

    Benzinga | Jan. 16, 2014 | 14:30PM EST
  11. Morning Market Movers

    Benzinga | Dec. 19, 2013 | 10:04AM EST
  12. Benzinga's Top #PreMarket Gainers

    Benzinga | Dec. 19, 2013 | 08:17AM EST
  13. Alimera Sciences Receives FDA CRL for ILUVIEN

    Benzinga | Oct. 18, 2013 | 06:31AM EST
  14. Earnings Scheduled For August 12, 2013

    Benzinga | Aug. 12, 2013 | 04:54AM EST
  15. Alimera Sciences, Inc. (ALIM) CFO Richard S Jr Eiswirth buys 5,000 Shares

    GuruFocus | Dec. 17, 2012 | 11:36AM EST
  16. Alimera Sciences, Inc. (ALIM) President and CEO C. Daniel Myers sells 7,700 Shares

    GuruFocus | Dec. 5, 2012 | 11:06AM EST
  17. UPDATE: Oppenheimer Reiterates Outperform Rating, Lowers PT on Alimera Sciences

    Benzinga | Nov. 30, 2012 | 03:35AM EST
  18. U.K.'s NICE Says Alimera's ILUVIEN Not Recommended for Treatment of Chronic Diabetic Macular Edema

    Benzinga | Nov. 29, 2012 | 13:38PM EST
  19. Alimera Sciences, Inc. (ALIM) President and CEO C. Daniel Myers sells 5,950 Shares

    GuruFocus | Nov. 5, 2012 | 11:41AM EST
  20. Alimera Sciences Closes $40 Million Financing

    Benzinga | Oct. 2, 2012 | 11:02AM EST
  21. Alimera Sciences' ILUVIEN Receives Marketing Authorization in Germany for the Treatment of Chronic Diabetic Macular Edema

    Benzinga | Jul. 26, 2012 | 01:15AM EST
  22. Health Care Sector Wrap

    FoxBusiness | Jul. 20, 2012 | 10:40AM EST
  23. Health Care Sector Wrap

    FoxBusiness | Jun. 25, 2012 | 10:45AM EST
  24. Earnings Scheduled For May 11

    Benzinga | May. 10, 2012 | 21:14PM EST
  25. Oppenheimer Increases Alimera Sciences PT

    Benzinga | Feb. 28, 2012 | 09:38AM EST
  26. Benzinga's Top Pre-Market Gainers

    Benzinga | Feb. 28, 2012 | 01:07AM EST
  27. Financial Breakfast: Morning News Summary for February 28, 2012

    Benzinga | Feb. 28, 2012 | 00:23AM EST
  28. Alimera Sciences Announces Positive Outcome to the European Decentralized Procedure for Approval of ILUVIEN for the Treatment of Chronic Diabetic Macular Edema

    Benzinga | Feb. 27, 2012 | 23:45PM EST
  29. Benzinga's Microcap Movers for Monday February 27, 2012

    Benzinga | Feb. 27, 2012 | 13:30PM EST
  30. Microcap Movers for Monday December 12, 2011

    Benzinga | Dec. 12, 2011 | 10:43AM EST
Trading Center